SCYNEXIS, Inc. Receives Preclinical Milestone Payment In Collaboration With Merck & Co., Inc.
RESEARCH TRIANGLE PARK, NC -- (MARKET WIRE) -- January 09, 2007 -- SCYNEXIS, Inc. today announced that it has earned a $1 million payment from Merck & Co., Inc. for meeting certain preclinical milestones in the companies' collaboration to develop novel antifungal agents.